<i id='A70A1BF315'><strike id='A70A1BF315'><tt id='A70A1BF315'><pre id='A70A1BF315'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Heart attack and stroke risk calculators need revising 
Twill hunts for pharma partner to market its depression app 
Wildfire smoke exposes gaps in outdoor worker protections
Twill hunts for pharma partner to market its depression app 
New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum 
UK homeowners get some respite as inflation falls by more than anticipated to a 15 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024 
Medicare proposal to cover medical devices draws a mixed reaction 
Delta passengers in Vegas fall sick while waiting on flight in triple 
Jerome Adams on the need for new antivirals for Covid 
DeSantis says Trump could've 'come out more forcefully' during Jan. 6 
Hollywood unions extend contract negotiations for actors 
Robert Kennedy Jr.'s presidential campaign attracts GOP 
How to save PrEP access — and even expand it 
